{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T07:05:20Z","timestamp":1778223920865,"version":"3.51.4"},"reference-count":34,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2016,6,9]],"date-time":"2016-06-09T00:00:00Z","timestamp":1465430400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2016,10]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>The objective of this study was to estimate the cost\u2010effectiveness of treating patients infected with <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content> and simultaneously coinfected with tuberculosis (<jats:styled-content style=\"fixed-case\">TB<\/jats:styled-content>) and hepatitis C virus (<jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A mathematical model for <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content> coinfection with <jats:styled-content style=\"fixed-case\">TB<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> is introduced. The model was designed to incorporate parameters of control for the coverage of care, which makes it useful for performing cost\u2010effectiveness analysis of public policies. A cost\u2010effectiveness analysis of early medical care of patients with <jats:styled-content style=\"fixed-case\">TB<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> coinfection, with coverage of 0 (basal), 25, 50, 75 and 100%, was performed for the whole cohort of patients and a special analysis was performed in a selected population with triple infection.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The cost per resolved infection and the cost per year of life gained were found to be very cost\u2010effective for the population with triple infection, for all different coverages.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>It is known that treating patients with <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content> who are coinfected with <jats:styled-content style=\"fixed-case\">TB<\/jats:styled-content> or <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content> implies high cost and low efficacy, but it is possible that the population with triple infections could achieve important benefits in terms of years of life gained.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hiv.12372","type":"journal-article","created":{"date-parts":[[2016,6,9]],"date-time":"2016-06-09T09:35:38Z","timestamp":1465464938000},"page":"674-682","source":"Crossref","is-referenced-by-count":2,"title":["The cost\u2010effectiveness of treating triple coinfection with <scp>HIV<\/scp>, tuberculosis and hepatitis C virus"],"prefix":"10.1111","volume":"17","author":[{"given":"G","family":"S\u00e1nchez\u2010Gonz\u00e1lez","sequence":"first","affiliation":[{"name":"Immunology Division National Institute of Public Health Cuernavaca Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,6,9]]},"reference":[{"key":"e_1_2_6_2_1","unstructured":"TsertsvadzeTN ChkhartishviliA RukhadzeGNet al.Analysis of causes of death among HIV\u2010infected persons in Georgia 1989\u20102009. AIDS 2010\u2013XVIII International AIDS Conference: Abstract no. TUPE0225."},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis404"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1086\/338641"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08904-3"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0b013e32834bcbd9"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)70733-9"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.7734"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.12754"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000093"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-13-190"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27151"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0059546"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00067114"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3283471cce"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2009.01232.x"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055373"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.10.0686"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055824"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1086\/651686"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1086\/651492"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa031667"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.07.012"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1086\/650529"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-012-0352-4"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-5-130"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/569692"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03405248"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2006.06.036"},{"key":"e_1_2_6_30_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2807\/ese.13.22.18888-en","article-title":"Prevalence of hepatitis C and hepatitis B infection in the HIV\u2010infected population of France, 2004","volume":"13","author":"Larsen C","year":"2008","journal-title":"Euro Surveill"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-004-3063-7"},{"key":"e_1_2_6_32_1","first-page":"8","article-title":"Prevalence of TB\/HIV co\u2010infection in countries except China: a systematic review and meta\u2010analysis","volume":"31","author":"Gao J","year":"2013","journal-title":"PLoS ONE"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-8-266"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2231"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3283533ae2"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fhiv.12372","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.12372","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T10:13:44Z","timestamp":1695550424000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.12372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,9]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["10.1111\/hiv.12372"],"URL":"https:\/\/doi.org\/10.1111\/hiv.12372","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,9]]}}}